Equities Analysts Offer Predictions for BEAM Q1 Earnings

Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Stock analysts at Wedbush decreased their Q1 2025 EPS estimates for shares of Beam Therapeutics in a note issued to investors on Tuesday, February 25th. Wedbush analyst D. Nierengarten now expects that the company will earn ($1.21) per share for the quarter, down from their prior forecast of ($1.16). Wedbush currently has a "Outperform" rating and a $57.00 target price on the stock. The consensus estimate for Beam Therapeutics' current full-year earnings is ($4.57) per share. Wedbush also issued estimates for Beam Therapeutics' Q2 2025 earnings at ($1.18) EPS, Q3 2025 earnings at ($1.18) EPS, Q4 2025 earnings at ($1.24) EPS, FY2025 earnings at ($4.81) EPS, FY2026 earnings at ($5.60) EPS, FY2027 earnings at ($5.42) EPS and FY2028 earnings at ($4.15) EPS.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($1.09) EPS for the quarter, beating the consensus estimate of ($1.25) by $0.16. The firm had revenue of $30.00 million during the quarter, compared to analysts' expectations of $16.47 million. Beam Therapeutics had a negative return on equity of 16.22% and a negative net margin of 41.07%. The business's quarterly revenue was down 90.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.73 earnings per share.

Several other brokerages also recently issued reports on BEAM. HC Wainwright reiterated a "buy" rating and issued a $80.00 target price on shares of Beam Therapeutics in a research note on Friday. Leerink Partnrs upgraded Beam Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, November 6th. Sanford C. Bernstein raised shares of Beam Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, January 7th. Royal Bank of Canada increased their price target on shares of Beam Therapeutics from $24.00 to $26.00 and gave the company a "sector perform" rating in a report on Wednesday. Finally, Guggenheim restated a "buy" rating and set a $78.00 price objective on shares of Beam Therapeutics in a report on Thursday. Two analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $50.90.

Remove Ads

Beam Therapeutics Price Performance

BEAM stock traded down $0.77 during trading hours on Thursday, reaching $26.34. The stock had a trading volume of 1,469,610 shares, compared to its average volume of 1,297,222. The stock has a market capitalization of $2.20 billion, a PE ratio of -14.97 and a beta of 1.92. The stock has a 50-day simple moving average of $27.18 and a 200 day simple moving average of $25.94. Beam Therapeutics has a fifty-two week low of $20.84 and a fifty-two week high of $45.05.

Institutional Trading of Beam Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Wealthfront Advisers LLC bought a new position in shares of Beam Therapeutics in the fourth quarter worth about $41,000. GF Fund Management CO. LTD. bought a new position in shares of Beam Therapeutics in the 4th quarter valued at $43,000. Sterling Capital Management LLC lifted its stake in shares of Beam Therapeutics by 816.0% in the 4th quarter. Sterling Capital Management LLC now owns 2,409 shares of the company's stock valued at $60,000 after acquiring an additional 2,146 shares during the last quarter. Blue Trust Inc. raised its position in Beam Therapeutics by 84.0% in the third quarter. Blue Trust Inc. now owns 3,135 shares of the company's stock valued at $73,000 after purchasing an additional 1,431 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in Beam Therapeutics by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,981 shares of the company's stock valued at $75,000 after purchasing an additional 524 shares during the last quarter. 99.68% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CEO John M. Evans sold 30,000 shares of the company's stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $26.75, for a total transaction of $802,500.00. Following the completion of the sale, the chief executive officer now owns 908,659 shares of the company's stock, valued at $24,306,628.25. This represents a 3.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Christine Bellon sold 1,241 shares of the company's stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $24.68, for a total transaction of $30,627.88. Following the sale, the insider now directly owns 102,968 shares of the company's stock, valued at approximately $2,541,250.24. This trade represents a 1.19 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 4.20% of the company's stock.

Beam Therapeutics Company Profile

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.